person · Reporting owner

Kim Helen Susan

Disclosed activity across 6 companies

Tapewire entity: 69539
SEC CIK: 0001422772

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ASSEMBLY BIOSCIENCES, INC.ASMB · Entity 5216	Director	June 11, 2020	June 15, 2020
Aktis Oncology, Inc.AKTS · Entity 4711	Director · 10% owner	January 12, 2026	January 12, 2026
Applied Molecular Transport Inc.AMTI · Entity 95737	Director	August 26, 2021	August 27, 2021
EXICURE, INC.XCUR · Entity 8068	Director	June 04, 2020	June 08, 2020
PROTHENA CORP PUBLIC LTD COPRTA · Entity 2375	Director	May 14, 2025	May 16, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ASSEMBLY BIOSCIENCES, INC.

Report date June 11, 2020 · Filed June 15, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.47 · Expires 2030-06-11	Direct	10,000	Reported balance After 2020-06-11 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-06-11 · Grant · Acquired 10,000 · Balance 10,000 F1: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) June 11, 2021 and (2) the date of the Issuer's 2021 annual meeting of stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) June 11, 2021 and (2) the date of the Issuer's 2021 annual meeting of stockholders.

Aktis Oncology, Inc.

Report date January 12, 2026 · Filed January 12, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	4,859,370	Reported balance After 2026-01-12 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2026-01-12 · Conversion · Acquired 4,859,370 · Balance 4,859,370 F1: Represents shares of the Issuer's Common Stock received upon conversion of shares of the Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock on a 3.8044-for-1 basis without payment of additional consideration. F2: These shares are held by Vida Ventures II, LLC ("VV II"). VV Manager II, LLC ("VVM II") is the manager of VV II and may be deemed to have voting, investment and dispositive power with respect to the shares held by VV II. Arie Belldegrun, Fred Cohen, and Leonard Potter, the members of the management committee of VVM II, along with the other members of the investment committee of VVM II, Rajul Jain, Joshua Kazam, and the Reporting Person, a member of the Issuer's board of directors, may be deemed to share voting, investment and dispositive power over the shares held by VV II and each such person disclaims beneficial ownership of the securities except to the extent of such person's pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	5,671,825	Reported balance After 2026-01-12 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2026-01-12 · Purchase · Acquired 812,455 · Balance 5,671,825 F2: These shares are held by Vida Ventures II, LLC ("VV II"). VV Manager II, LLC ("VVM II") is the manager of VV II and may be deemed to have voting, investment and dispositive power with respect to the shares held by VV II. Arie Belldegrun, Fred Cohen, and Leonard Potter, the members of the management committee of VVM II, along with the other members of the investment committee of VVM II, Rajul Jain, Joshua Kazam, and the Reporting Person, a member of the Issuer's board of directors, may be deemed to share voting, investment and dispositive power over the shares held by VV II and each such person disclaims beneficial ownership of the securities except to the extent of such person's pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	134,842	Reported balance After 2026-01-12 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2026-01-12 · Conversion · Acquired 134,842 · Balance 134,842 F1: Represents shares of the Issuer's Common Stock received upon conversion of shares of the Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock on a 3.8044-for-1 basis without payment of additional consideration. F3: These shares are held by Vida Ventures II-A, LLC ("VV II-A"). VVM II is the manager of VV II-A and may be deemed to have voting, investment and dispositive power with respect to the shares held by VV II-A. Arie Belldegrun, Fred Cohen, and Leonard Potter, the members of the management committee of VVM II, along with the other members of the investment committee of VVM II, Rajul Jain, Joshua Kazam, and the Reporting Person, a member of the Issuer's board of directors, may be deemed to share voting, investment and dispositive power over the shares held by VV II-A and each such person disclaims beneficial ownership of the securities except to the extent of such person's pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	157,387	Reported balance After 2026-01-12 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 4 · 2026-01-12 · Purchase · Acquired 22,545 · Balance 157,387 F3: These shares are held by Vida Ventures II-A, LLC ("VV II-A"). VVM II is the manager of VV II-A and may be deemed to have voting, investment and dispositive power with respect to the shares held by VV II-A. Arie Belldegrun, Fred Cohen, and Leonard Potter, the members of the management committee of VVM II, along with the other members of the investment committee of VVM II, Rajul Jain, Joshua Kazam, and the Reporting Person, a member of the Issuer's board of directors, may be deemed to share voting, investment and dispositive power over the shares held by VV II-A and each such person disclaims beneficial ownership of the securities except to the extent of such person's pecuniary interest therein.
Series A Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2026-01-12 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-01-12 · Conversion · Disposed 14,838,250 · Balance 0 F4: The Series A Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration. F2: These shares are held by Vida Ventures II, LLC ("VV II"). VV Manager II, LLC ("VVM II") is the manager of VV II and may be deemed to have voting, investment and dispositive power with respect to the shares held by VV II. Arie Belldegrun, Fred Cohen, and Leonard Potter, the members of the management committee of VVM II, along with the other members of the investment committee of VVM II, Rajul Jain, Joshua Kazam, and the Reporting Person, a member of the Issuer's board of directors, may be deemed to share voting, investment and dispositive power over the shares held by VV II and each such person disclaims beneficial ownership of the securities except to the extent of such person's pecuniary interest therein.
Series A Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2026-01-12 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-01-12 · Conversion · Disposed 411,750 · Balance 0 F4: The Series A Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration. F3: These shares are held by Vida Ventures II-A, LLC ("VV II-A"). VVM II is the manager of VV II-A and may be deemed to have voting, investment and dispositive power with respect to the shares held by VV II-A. Arie Belldegrun, Fred Cohen, and Leonard Potter, the members of the management committee of VVM II, along with the other members of the investment committee of VVM II, Rajul Jain, Joshua Kazam, and the Reporting Person, a member of the Issuer's board of directors, may be deemed to share voting, investment and dispositive power over the shares held by VV II-A and each such person disclaims beneficial ownership of the securities except to the extent of such person's pecuniary interest therein.
Series B Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2026-01-12 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-01-12 · Conversion · Disposed 3,648,750 · Balance 0 F5: The Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration. F2: These shares are held by Vida Ventures II, LLC ("VV II"). VV Manager II, LLC ("VVM II") is the manager of VV II and may be deemed to have voting, investment and dispositive power with respect to the shares held by VV II. Arie Belldegrun, Fred Cohen, and Leonard Potter, the members of the management committee of VVM II, along with the other members of the investment committee of VVM II, Rajul Jain, Joshua Kazam, and the Reporting Person, a member of the Issuer's board of directors, may be deemed to share voting, investment and dispositive power over the shares held by VV II and each such person disclaims beneficial ownership of the securities except to the extent of such person's pecuniary interest therein.
Series B Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2026-01-12 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2026-01-12 · Conversion · Disposed 101,250 · Balance 0 F5: The Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration. F3: These shares are held by Vida Ventures II-A, LLC ("VV II-A"). VVM II is the manager of VV II-A and may be deemed to have voting, investment and dispositive power with respect to the shares held by VV II-A. Arie Belldegrun, Fred Cohen, and Leonard Potter, the members of the management committee of VVM II, along with the other members of the investment committee of VVM II, Rajul Jain, Joshua Kazam, and the Reporting Person, a member of the Issuer's board of directors, may be deemed to share voting, investment and dispositive power over the shares held by VV II-A and each such person disclaims beneficial ownership of the securities except to the extent of such person's pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of the Issuer's Common Stock received upon conversion of shares of the Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock on a 3.8044-for-1 basis without payment of additional consideration.

F2: These shares are held by Vida Ventures II, LLC ("VV II"). VV Manager II, LLC ("VVM II") is the manager of VV II and may be deemed to have voting, investment and dispositive power with respect to the shares held by VV II. Arie Belldegrun, Fred Cohen, and Leonard Potter, the members of the management committee of VVM II, along with the other members of the investment committee of VVM II, Rajul Jain, Joshua Kazam, and the Reporting Person, a member of the Issuer's board of directors, may be deemed to share voting, investment and dispositive power over the shares held by VV II and each such person disclaims beneficial ownership of the securities except to the extent of such person's pecuniary interest therein.

F3: These shares are held by Vida Ventures II-A, LLC ("VV II-A"). VVM II is the manager of VV II-A and may be deemed to have voting, investment and dispositive power with respect to the shares held by VV II-A. Arie Belldegrun, Fred Cohen, and Leonard Potter, the members of the management committee of VVM II, along with the other members of the investment committee of VVM II, Rajul Jain, Joshua Kazam, and the Reporting Person, a member of the Issuer's board of directors, may be deemed to share voting, investment and dispositive power over the shares held by VV II-A and each such person disclaims beneficial ownership of the securities except to the extent of such person's pecuniary interest therein.

F4: The Series A Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration.

F5: The Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration.

Applied Molecular Transport Inc.

Report date August 26, 2021 · Filed August 27, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	575,000	Ending reported balance After 2021-08-27 transaction · row 4 4 source rows · reconciled sequence Row 1 · 2021-08-26 · Sale · Disposed 13,505 · Balance 576,509 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on July 7, 2021. F2: The price reported in column is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.915, inclusive. The reporting person undertakes to provide Applied Molecular Transport, Inc., any security holder of Applied Molecular Transport, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 2 · 2021-08-26 · Sale · Disposed 558 · Balance 575,951 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on July 7, 2021. F3: The price reported in column is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.00 to $31.045, inclusive. The reporting person undertakes to provide Applied Molecular Transport, Inc., any security holder of Applied Molecular Transport, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2021-08-27 · Sale · Disposed 701 · Balance 575,250 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on July 7, 2021. F4: The price reported in column is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.25 to $31.24, inclusive. The reporting person undertakes to provide Applied Molecular Transport, Inc., any security holder of Applied Molecular Transport, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 4 · 2021-08-27 · Sale · Disposed 250 · Balance 575,000 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on July 7, 2021. F5: The price reported in column is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.25 to $31.98, inclusive. The reporting person undertakes to provide Applied Molecular Transport, Inc., any security holder of Applied Molecular Transport, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Filing footnotes · ownership attribution and instrument terms

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on July 7, 2021.

F2: The price reported in column is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.915, inclusive. The reporting person undertakes to provide Applied Molecular Transport, Inc., any security holder of Applied Molecular Transport, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The price reported in column is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.00 to $31.045, inclusive. The reporting person undertakes to provide Applied Molecular Transport, Inc., any security holder of Applied Molecular Transport, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The price reported in column is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.25 to $31.24, inclusive. The reporting person undertakes to provide Applied Molecular Transport, Inc., any security holder of Applied Molecular Transport, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F5: The price reported in column is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.25 to $31.98, inclusive. The reporting person undertakes to provide Applied Molecular Transport, Inc., any security holder of Applied Molecular Transport, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

EXICURE, INC.

Report date June 04, 2020 · Filed June 08, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.79 · Expires 2030-06-03	Direct	21,693	Reported balance After 2020-06-04 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-06-04 · Grant · Acquired 21,693 · Balance 21,693 F1: The shares subject to the option will vest as to 1/12 of the underlying shares monthly from the vesting commencement date of June 4, 2020, provided the Reporting Person remains in continuous service on each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to the option will vest as to 1/12 of the underlying shares monthly from the vesting commencement date of June 4, 2020, provided the Reporting Person remains in continuous service on each vesting date.

PROTHENA CORP PUBLIC LTD CO

Report date May 14, 2025 · Filed May 16, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.89 · Expires 2035-05-14	Direct	20,183	Reported balance After 2025-05-14 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-05-14 · Grant · Acquired 20,183 · Balance 20,183 F1: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2026 of the Issuer's shareholders, assuming continuous service as a director until such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2026 of the Issuer's shareholders, assuming continuous service as a director until such vesting date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Kite Pharma, Inc.

Report date October 03, 2017 · Filed October 05, 2017

Section 16 reporting ended · disclosed 2017-10-05. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Ending reported balance After 2017-10-03 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2017-10-03 · Other · Disposed 4,193 · Balance 17,500 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F2: Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Notes 3 and 4 below, was validly tendered for $180 per share in cash, without interest and subject to any required withholding of taxes. Row 2 · 2017-10-03 · Disposition to issuer · Disposed 17,500 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F3: Represents shares of Company common stock underlying restricted stock units with respect to Company common stock, including all time-vesting and all performance-vesting restricted stock units (each a "Company Restricted Stock Unit"), held by the Reporting Person. F4: Pursuant to the terms of the Merger Agreement, each Company Restricted Stock Unit was assumed and converted into a restricted stock unit denominated in shares of Parent common stock, on the same terms and conditions as were then applicable under such Company Restricted Stock Unit (including applicable performance vesting conditions), and relating to a number of shares of Parent common stock equal to the product of (i) the total number of shares of Company common stock subject to such Company Restricted Stock Unit multiplied by (ii) the quotient of (A) $180.00 divided by (B) the volume-weighted average closing sale price of a share of Parent common stock for the fifteen full consecutive trading days ending on and including September 28, 2017 ($83.12) (such quotient, the "Equity Award Conversion Ratio").
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.90 · Expires 2024-12-14	Direct	Reported balance After 2017-10-03 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2017-10-03 · Disposition to issuer · Disposed 3,752 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F6: This vested option was cancelled at the effective time of the Merger in exchange for a cash payment equal to $180.00, less the exercise price of the option. F5: This option provided for 25% vesting on November 10, 2015, and vesting thereafter in 36 equal monthly installments.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.90 · Expires 2024-12-14	Direct	Reported balance After 2017-10-03 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2017-10-03 · Disposition to issuer · Disposed 52,500 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F7: Pursuant to the terms of the Merger Agreement, each option to purchase Company common stock (each, a "Company Option") then outstanding and unexercised, other than any vested in-the-money Company Option, was assumed and converted into an option to purchase a number of shares of Parent common stock, on the same terms and subject to the same conditions as were applicable to such Company Option, equal to the product of (i) the total number of shares of Company common stock subject to such Company Option multiplied by (ii) the Equity Award Conversion Ratio, and with an exercise price equal to the quotient of (i) the exercise price of such Company Option divided by (ii) the Equity Award Conversion Ratio. F5: This option provided for 25% vesting on November 10, 2015, and vesting thereafter in 36 equal monthly installments.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.43 · Expires 2025-05-18	Direct	Reported balance After 2017-10-03 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2017-10-03 · Disposition to issuer · Disposed 2,499 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F6: This vested option was cancelled at the effective time of the Merger in exchange for a cash payment equal to $180.00, less the exercise price of the option. F5: This option provided for 25% vesting on November 10, 2015, and vesting thereafter in 36 equal monthly installments.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.43 · Expires 2025-05-18	Direct	Reported balance After 2017-10-03 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2017-10-03 · Disposition to issuer · Disposed 35,000 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F7: Pursuant to the terms of the Merger Agreement, each option to purchase Company common stock (each, a "Company Option") then outstanding and unexercised, other than any vested in-the-money Company Option, was assumed and converted into an option to purchase a number of shares of Parent common stock, on the same terms and subject to the same conditions as were applicable to such Company Option, equal to the product of (i) the total number of shares of Company common stock subject to such Company Option multiplied by (ii) the Equity Award Conversion Ratio, and with an exercise price equal to the quotient of (i) the exercise price of such Company Option divided by (ii) the Equity Award Conversion Ratio. F5: This option provided for 25% vesting on November 10, 2015, and vesting thereafter in 36 equal monthly installments.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.87 · Expires 2025-12-16	Direct	Reported balance After 2017-10-03 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2017-10-03 · Disposition to issuer · Disposed 14,438 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F6: This vested option was cancelled at the effective time of the Merger in exchange for a cash payment equal to $180.00, less the exercise price of the option. F8: This option provided for 25% vesting on December 17, 2016, and vesting thereafter in 36 equal monthly installments.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.87 · Expires 2025-12-16	Direct	Reported balance After 2017-10-03 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2017-10-03 · Disposition to issuer · Disposed 18,562 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F7: Pursuant to the terms of the Merger Agreement, each option to purchase Company common stock (each, a "Company Option") then outstanding and unexercised, other than any vested in-the-money Company Option, was assumed and converted into an option to purchase a number of shares of Parent common stock, on the same terms and subject to the same conditions as were applicable to such Company Option, equal to the product of (i) the total number of shares of Company common stock subject to such Company Option multiplied by (ii) the Equity Award Conversion Ratio, and with an exercise price equal to the quotient of (i) the exercise price of such Company Option divided by (ii) the Equity Award Conversion Ratio. F8: This option provided for 25% vesting on December 17, 2016, and vesting thereafter in 36 equal monthly installments.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.09 · Expires 2026-12-21	Direct	Reported balance After 2017-10-03 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2017-10-03 · Disposition to issuer · Disposed 38,500 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F7: Pursuant to the terms of the Merger Agreement, each option to purchase Company common stock (each, a "Company Option") then outstanding and unexercised, other than any vested in-the-money Company Option, was assumed and converted into an option to purchase a number of shares of Parent common stock, on the same terms and subject to the same conditions as were applicable to such Company Option, equal to the product of (i) the total number of shares of Company common stock subject to such Company Option multiplied by (ii) the Equity Award Conversion Ratio, and with an exercise price equal to the quotient of (i) the exercise price of such Company Option divided by (ii) the Equity Award Conversion Ratio. F9: This option provides for 25% vesting on December 22, 2017, and vesting thereafter in 36 equal monthly installments.

Filing footnotes · ownership attribution and instrument terms

F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent.

F2: Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Notes 3 and 4 below, was validly tendered for $180 per share in cash, without interest and subject to any required withholding of taxes.

F3: Represents shares of Company common stock underlying restricted stock units with respect to Company common stock, including all time-vesting and all performance-vesting restricted stock units (each a "Company Restricted Stock Unit"), held by the Reporting Person.

F4: Pursuant to the terms of the Merger Agreement, each Company Restricted Stock Unit was assumed and converted into a restricted stock unit denominated in shares of Parent common stock, on the same terms and conditions as were then applicable under such Company Restricted Stock Unit (including applicable performance vesting conditions), and relating to a number of shares of Parent common stock equal to the product of (i) the total number of shares of Company common stock subject to such Company Restricted Stock Unit multiplied by (ii) the quotient of (A) $180.00 divided by (B) the volume-weighted average closing sale price of a share of Parent common stock for the fifteen full consecutive trading days ending on and including September 28, 2017 ($83.12) (such quotient, the "Equity Award Conversion Ratio").

F5: This option provided for 25% vesting on November 10, 2015, and vesting thereafter in 36 equal monthly installments.

F6: This vested option was cancelled at the effective time of the Merger in exchange for a cash payment equal to $180.00, less the exercise price of the option.

F7: Pursuant to the terms of the Merger Agreement, each option to purchase Company common stock (each, a "Company Option") then outstanding and unexercised, other than any vested in-the-money Company Option, was assumed and converted into an option to purchase a number of shares of Parent common stock, on the same terms and subject to the same conditions as were applicable to such Company Option, equal to the product of (i) the total number of shares of Company common stock subject to such Company Option multiplied by (ii) the Equity Award Conversion Ratio, and with an exercise price equal to the quotient of (i) the exercise price of such Company Option divided by (ii) the Equity Award Conversion Ratio.

F8: This option provided for 25% vesting on December 17, 2016, and vesting thereafter in 36 equal monthly installments.

F9: This option provides for 25% vesting on December 22, 2017, and vesting thereafter in 36 equal monthly installments.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 08, 2017 Filed Aug 10, 2017 16:57 UTC	Kite Pharma, Inc. KITE · Entity 172664	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	79,949	$0.00 Strike: $53.90	$0.00	Disclosure SEC source: 0001209191-17-048434 · doc4.xml · derivative · entry 8 Kim Helen Susan · CIK 0001422772 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,002 Underlying: Common Stock · 79,949 shares Expires 2024-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: 25% of the 180,000 shares subject to the stock option vested and became exercisable on November 10, 2015, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document
August 08, 2017 Filed Aug 10, 2017 16:57 UTC	Kite Pharma, Inc. KITE · Entity 172664	SaleCommon Stock	13,274	$121.37	$1,611,065.38	Disclosure SEC source: 0001209191-17-048434 · doc4.xml · nonDerivative · entry 7 Kim Helen Susan · CIK 0001422772 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,664 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 29, 2017. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.04 to $121.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
August 08, 2017 Filed Aug 10, 2017 16:57 UTC	Kite Pharma, Inc. KITE · Entity 172664	SaleCommon Stock	31,165	$120.40	$3,752,266.00	Disclosure SEC source: 0001209191-17-048434 · doc4.xml · nonDerivative · entry 6 Kim Helen Susan · CIK 0001422772 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,938 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 29, 2017. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.04 to $121.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
August 08, 2017 Filed Aug 10, 2017 16:57 UTC	Kite Pharma, Inc. KITE · Entity 172664	SaleCommon Stock	18,936	$119.94	$2,271,183.84	Disclosure SEC source: 0001209191-17-048434 · doc4.xml · nonDerivative · entry 5 Kim Helen Susan · CIK 0001422772 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,103 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 29, 2017. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.04 to $120.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
August 08, 2017 Filed Aug 10, 2017 16:57 UTC	Kite Pharma, Inc. KITE · Entity 172664	SaleCommon Stock	3,800	$118.61	$450,718.00	Disclosure SEC source: 0001209191-17-048434 · doc4.xml · nonDerivative · entry 4 Kim Helen Susan · CIK 0001422772 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,039 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 29, 2017. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.04 to $119.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
August 08, 2017 Filed Aug 10, 2017 16:57 UTC	Kite Pharma, Inc. KITE · Entity 172664	SaleCommon Stock	1,700	$117.27	$199,359.00	Disclosure SEC source: 0001209191-17-048434 · doc4.xml · nonDerivative · entry 3 Kim Helen Susan · CIK 0001422772 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,839 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 29, 2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.90 to $117.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
August 08, 2017 Filed Aug 10, 2017 16:57 UTC	Kite Pharma, Inc. KITE · Entity 172664	SaleCommon Stock	11,074	$115.02	$1,273,731.48	Disclosure SEC source: 0001209191-17-048434 · doc4.xml · nonDerivative · entry 2 Kim Helen Susan · CIK 0001422772 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,539 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 29, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.00 to $115.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
August 08, 2017 Filed Aug 10, 2017 16:57 UTC	Kite Pharma, Inc. KITE · Entity 172664	Exercise / conversionCommon Stock	79,949	$53.90	$4,309,251.10	Disclosure SEC source: 0001209191-17-048434 · doc4.xml · nonDerivative · entry 1 Kim Helen Susan · CIK 0001422772 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,613 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
July 31, 2017 Filed Aug 1, 2017 19:00 UTC	Kite Pharma, Inc. KITE · Entity 172664	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	16,550	$0.00 Strike: $53.90	$0.00	Disclosure SEC source: 0001209191-17-046974 · doc4.xml · derivative · entry 8 Kim Helen Susan · CIK 0001422772 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,951 Underlying: Common Stock · 16,550 shares Expires 2024-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: 25% of the 180,000 shares subject to the stock option vested and became exercisable on November 10, 2015, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document
July 31, 2017 Filed Aug 1, 2017 19:00 UTC	Kite Pharma, Inc. KITE · Entity 172664	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	10,099	$0.00 Strike: $51.43	$0.00	Disclosure SEC source: 0001209191-17-046974 · doc4.xml · derivative · entry 7 Kim Helen Susan · CIK 0001422772 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 10,099 shares Expires 2025-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 25% of the 120,000 shares subject to the stock option vested and became exercisable on November 10, 2015, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document
July 31, 2017 Filed Aug 1, 2017 19:00 UTC	Kite Pharma, Inc. KITE · Entity 172664	SaleCommon Stock	672	$111.60	$74,995.20	Disclosure SEC source: 0001209191-17-046974 · doc4.xml · nonDerivative · entry 6 Kim Helen Susan · CIK 0001422772 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,664 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 29, 2017. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.50 to $111.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
July 31, 2017 Filed Aug 1, 2017 19:00 UTC	Kite Pharma, Inc. KITE · Entity 172664	SaleCommon Stock	2,725	$110.55	$301,248.75	Disclosure SEC source: 0001209191-17-046974 · doc4.xml · nonDerivative · entry 5 Kim Helen Susan · CIK 0001422772 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,336 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 29, 2017. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.32 to $111.21, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
July 31, 2017 Filed Aug 1, 2017 19:00 UTC	Kite Pharma, Inc. KITE · Entity 172664	SaleCommon Stock	7,448	$109.74	$817,343.52	Disclosure SEC source: 0001209191-17-046974 · doc4.xml · nonDerivative · entry 4 Kim Helen Susan · CIK 0001422772 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,061 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 29, 2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.32 to $110.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
July 31, 2017 Filed Aug 1, 2017 19:00 UTC	Kite Pharma, Inc. KITE · Entity 172664	SaleCommon Stock	15,804	$108.75	$1,718,685.00	Disclosure SEC source: 0001209191-17-046974 · doc4.xml · nonDerivative · entry 3 Kim Helen Susan · CIK 0001422772 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,509 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 29, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.30 to $109.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
July 31, 2017 Filed Aug 1, 2017 19:00 UTC	Kite Pharma, Inc. KITE · Entity 172664	Exercise / conversionCommon Stock	16,550	$53.90	$892,045.00	Disclosure SEC source: 0001209191-17-046974 · doc4.xml · nonDerivative · entry 2 Kim Helen Susan · CIK 0001422772 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,313 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
July 31, 2017 Filed Aug 1, 2017 19:00 UTC	Kite Pharma, Inc. KITE · Entity 172664	Exercise / conversionCommon Stock	10,099	$51.43	$519,391.57	Disclosure SEC source: 0001209191-17-046974 · doc4.xml · nonDerivative · entry 1 Kim Helen Susan · CIK 0001422772 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,763 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 01, 2017 Filed Jun 5, 2017 17:05 UTC	Kite Pharma, Inc. KITE · Entity 172664	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	2,400	$0.00 Strike: $51.43	$0.00	Disclosure SEC source: 0001209191-17-037803 · doc4.xml · derivative · entry 3 Kim Helen Susan · CIK 0001422772 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,099 Underlying: Common Stock · 2,400 shares Expires 2025-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the 120,000 shares subject to the stock option vested and became exercisable on November 10, 2015, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document
June 01, 2017 Filed Jun 5, 2017 17:05 UTC	Kite Pharma, Inc. KITE · Entity 172664	SaleCommon Stock	2,400	$72.45	$173,880.00	Disclosure SEC source: 0001209191-17-037803 · doc4.xml · nonDerivative · entry 2 Kim Helen Susan · CIK 0001422772 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,664 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 7, 2016. Read SEC document
June 01, 2017 Filed Jun 5, 2017 17:05 UTC	Kite Pharma, Inc. KITE · Entity 172664	Exercise / conversionCommon Stock	2,400	$51.43	$123,432.00	Disclosure SEC source: 0001209191-17-037803 · doc4.xml · nonDerivative · entry 1 Kim Helen Susan · CIK 0001422772 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,064 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 01, 2017 Filed May 3, 2017 18:08 UTC	Kite Pharma, Inc. KITE · Entity 172664	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	2,400	$0.00 Strike: $53.90	$0.00	Disclosure SEC source: 0001209191-17-029754 · doc4.xml · derivative · entry 3 Kim Helen Susan · CIK 0001422772 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,501 Underlying: Common Stock · 2,400 shares Expires 2024-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the 180,000 shares subject to the stock option vested and became exercisable on November 10, 2015, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document
May 01, 2017 Filed May 3, 2017 18:08 UTC	Kite Pharma, Inc. KITE · Entity 172664	SaleCommon Stock	2,400	$82.12	$197,088.00	Disclosure SEC source: 0001209191-17-029754 · doc4.xml · nonDerivative · entry 2 Kim Helen Susan · CIK 0001422772 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,664 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 7, 2016. Read SEC document
May 01, 2017 Filed May 3, 2017 18:08 UTC	Kite Pharma, Inc. KITE · Entity 172664	Exercise / conversionCommon Stock	2,400	$53.90	$129,360.00	Disclosure SEC source: 0001209191-17-029754 · doc4.xml · nonDerivative · entry 1 Kim Helen Susan · CIK 0001422772 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,064 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 03, 2017 Filed Apr 4, 2017 16:16 UTC	Kite Pharma, Inc. KITE · Entity 172664	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	2,400	$0.00 Strike: $53.90	$0.00	Disclosure SEC source: 0001209191-17-024743 · doc4.xml · derivative · entry 3 Kim Helen Susan · CIK 0001422772 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,901 Underlying: Common Stock · 2,400 shares Expires 2024-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the 180,000 shares subject to the stock option vested and became exercisable on November 10, 2015, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document
April 03, 2017 Filed Apr 4, 2017 16:16 UTC	Kite Pharma, Inc. KITE · Entity 172664	SaleCommon Stock	2,400	$81.80	$196,320.00	Disclosure SEC source: 0001209191-17-024743 · doc4.xml · nonDerivative · entry 2 Kim Helen Susan · CIK 0001422772 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,664 Read SEC document
April 03, 2017 Filed Apr 4, 2017 16:16 UTC	Kite Pharma, Inc. KITE · Entity 172664	Exercise / conversionCommon Stock	2,400	$53.90	$129,360.00	Disclosure SEC source: 0001209191-17-024743 · doc4.xml · nonDerivative · entry 1 Kim Helen Susan · CIK 0001422772 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,064 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 01, 2017 Filed Mar 2, 2017 06:05 UTC	Kite Pharma, Inc. KITE · Entity 172664	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	2,400	$0.00 Strike: $53.90	$0.00	Disclosure SEC source: 0000899243-17-005888 · doc4.xml · derivative · entry 24 Kim Helen Susan · CIK 0001422772 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,301 Underlying: Common Stock · 2,400 shares Expires 2024-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F19 · derivative.exercise_date: 25% of the 180,000 shares subject to the stock option vested and became exercisable on November 10, 2015, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document
March 01, 2017 Filed Mar 2, 2017 06:05 UTC	Kite Pharma, Inc. KITE · Entity 172664	SaleCommon Stock	400	$79.92	$31,968.00	Disclosure SEC source: 0000899243-17-005888 · doc4.xml · nonDerivative · entry 21 Kim Helen Susan · CIK 0001422772 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,664 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 7, 2016. F17 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.69 to $80.38 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
March 01, 2017 Filed Mar 2, 2017 06:05 UTC	Kite Pharma, Inc. KITE · Entity 172664	SaleCommon Stock	600	$79.26	$47,556.00	Disclosure SEC source: 0000899243-17-005888 · doc4.xml · nonDerivative · entry 20 Kim Helen Susan · CIK 0001422772 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,064 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 7, 2016. F16 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.65 to $79.61 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
March 01, 2017 Filed Mar 2, 2017 06:05 UTC	Kite Pharma, Inc. KITE · Entity 172664	SaleCommon Stock	200	$76.93	$15,386.00	Disclosure SEC source: 0000899243-17-005888 · doc4.xml · nonDerivative · entry 19 Kim Helen Susan · CIK 0001422772 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,664 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 7, 2016. F15 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.86 to $77.00 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
March 01, 2017 Filed Mar 2, 2017 06:05 UTC	Kite Pharma, Inc. KITE · Entity 172664	SaleCommon Stock	200	$75.52	$15,104.00	Disclosure SEC source: 0000899243-17-005888 · doc4.xml · nonDerivative · entry 18 Kim Helen Susan · CIK 0001422772 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,864 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 7, 2016. F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.25 to $75.79 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
March 01, 2017 Filed Mar 2, 2017 06:05 UTC	Kite Pharma, Inc. KITE · Entity 172664	SaleCommon Stock	100	$73.64	$7,364.00	Disclosure SEC source: 0000899243-17-005888 · doc4.xml · nonDerivative · entry 17 Kim Helen Susan · CIK 0001422772 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,064 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 7, 2016. Read SEC document
March 01, 2017 Filed Mar 2, 2017 06:05 UTC	Kite Pharma, Inc. KITE · Entity 172664	SaleCommon Stock	200	$72.69	$14,538.00	Disclosure SEC source: 0000899243-17-005888 · doc4.xml · nonDerivative · entry 16 Kim Helen Susan · CIK 0001422772 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,164 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 7, 2016. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.55 to $72.83 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
March 01, 2017 Filed Mar 2, 2017 06:05 UTC	Kite Pharma, Inc. KITE · Entity 172664	SaleCommon Stock	200	$71.23	$14,246.00	Disclosure SEC source: 0000899243-17-005888 · doc4.xml · nonDerivative · entry 15 Kim Helen Susan · CIK 0001422772 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,364 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 7, 2016. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.09 to $71.36 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
March 01, 2017 Filed Mar 2, 2017 06:05 UTC	Kite Pharma, Inc. KITE · Entity 172664	SaleCommon Stock	300	$70.29	$21,087.00	Disclosure SEC source: 0000899243-17-005888 · doc4.xml · nonDerivative · entry 14 Kim Helen Susan · CIK 0001422772 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,564 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 7, 2016. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.89 to $70.71 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
March 01, 2017 Filed Mar 2, 2017 06:05 UTC	Kite Pharma, Inc. KITE · Entity 172664	SaleCommon Stock	200	$68.95	$13,790.00	Disclosure SEC source: 0000899243-17-005888 · doc4.xml · nonDerivative · entry 13 Kim Helen Susan · CIK 0001422772 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,864 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 7, 2016. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.66 to $69.23 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
March 01, 2017 Filed Mar 2, 2017 06:05 UTC	Kite Pharma, Inc. KITE · Entity 172664	Exercise / conversionCommon Stock	2,400	$53.90	$129,360.00	Disclosure SEC source: 0000899243-17-005888 · doc4.xml · nonDerivative · entry 12 Kim Helen Susan · CIK 0001422772 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,064 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 28, 2017 Filed Mar 2, 2017 06:05 UTC	Kite Pharma, Inc. KITE · Entity 172664	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	16,299	$0.00 Strike: $53.90	$0.00	Disclosure SEC source: 0000899243-17-005888 · doc4.xml · derivative · entry 23 Kim Helen Susan · CIK 0001422772 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,701 Underlying: Common Stock · 16,299 shares Expires 2024-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F19 · derivative.exercise_date: 25% of the 180,000 shares subject to the stock option vested and became exercisable on November 10, 2015, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document
February 28, 2017 Filed Mar 2, 2017 06:05 UTC	Kite Pharma, Inc. KITE · Entity 172664	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	31,601	$0.00 Strike: $51.43	$0.00	Disclosure SEC source: 0000899243-17-005888 · doc4.xml · derivative · entry 22 Kim Helen Susan · CIK 0001422772 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,499 Underlying: Common Stock · 31,601 shares Expires 2025-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F18 · derivative.exercise_date: 25% of the 120,000 shares subject to the stock option vested and became exercisable on November 10, 2015, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document
February 28, 2017 Filed Mar 2, 2017 06:05 UTC	Kite Pharma, Inc. KITE · Entity 172664	SaleCommon Stock	300	$72.60	$21,780.00	Disclosure SEC source: 0000899243-17-005888 · doc4.xml · nonDerivative · entry 11 Kim Helen Susan · CIK 0001422772 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,664 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 7, 2016. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.59 to $72.60 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
February 28, 2017 Filed Mar 2, 2017 06:05 UTC	Kite Pharma, Inc. KITE · Entity 172664	SaleCommon Stock	1,800	$71.65	$128,970.00	Disclosure SEC source: 0000899243-17-005888 · doc4.xml · nonDerivative · entry 10 Kim Helen Susan · CIK 0001422772 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,964 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 7, 2016. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.54 to $71.80 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
February 28, 2017 Filed Mar 2, 2017 06:05 UTC	Kite Pharma, Inc. KITE · Entity 172664	SaleCommon Stock	9,049	$71.16	$643,926.84	Disclosure SEC source: 0000899243-17-005888 · doc4.xml · nonDerivative · entry 9 Kim Helen Susan · CIK 0001422772 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,764 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 7, 2016. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.54 to $71.52 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
February 28, 2017 Filed Mar 2, 2017 06:05 UTC	Kite Pharma, Inc. KITE · Entity 172664	SaleCommon Stock	2,553	$69.63	$177,765.39	Disclosure SEC source: 0000899243-17-005888 · doc4.xml · nonDerivative · entry 8 Kim Helen Susan · CIK 0001422772 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,813 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 7, 2016. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.25 to $69.91 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
February 28, 2017 Filed Mar 2, 2017 06:05 UTC	Kite Pharma, Inc. KITE · Entity 172664	SaleCommon Stock	900	$68.74	$61,866.00	Disclosure SEC source: 0000899243-17-005888 · doc4.xml · nonDerivative · entry 7 Kim Helen Susan · CIK 0001422772 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,366 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 7, 2016. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.25 to $69.19 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
February 28, 2017 Filed Mar 2, 2017 06:05 UTC	Kite Pharma, Inc. KITE · Entity 172664	SaleCommon Stock	2,500	$67.49	$168,725.00	Disclosure SEC source: 0000899243-17-005888 · doc4.xml · nonDerivative · entry 6 Kim Helen Susan · CIK 0001422772 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,266 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 7, 2016. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.00 to $67.91 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
February 28, 2017 Filed Mar 2, 2017 06:05 UTC	Kite Pharma, Inc. KITE · Entity 172664	SaleCommon Stock	10,326	$66.32	$684,820.32	Disclosure SEC source: 0000899243-17-005888 · doc4.xml · nonDerivative · entry 5 Kim Helen Susan · CIK 0001422772 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,766 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 7, 2016. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.00 to $66.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
February 28, 2017 Filed Mar 2, 2017 06:05 UTC	Kite Pharma, Inc. KITE · Entity 172664	SaleCommon Stock	18,072	$65.81	$1,189,318.32	Disclosure SEC source: 0000899243-17-005888 · doc4.xml · nonDerivative · entry 4 Kim Helen Susan · CIK 0001422772 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,092 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 7, 2016. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.00 to $65.99 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
February 28, 2017 Filed Mar 2, 2017 06:05 UTC	Kite Pharma, Inc. KITE · Entity 172664	SaleCommon Stock	2,400	$63.00	$151,200.00	Disclosure SEC source: 0000899243-17-005888 · doc4.xml · nonDerivative · entry 3 Kim Helen Susan · CIK 0001422772 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,164 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 7, 2016. Read SEC document
February 28, 2017 Filed Mar 2, 2017 06:05 UTC	Kite Pharma, Inc. KITE · Entity 172664	Exercise / conversionCommon Stock	16,299	$53.90	$878,516.10	Disclosure SEC source: 0000899243-17-005888 · doc4.xml · nonDerivative · entry 2 Kim Helen Susan · CIK 0001422772 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,564 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 28, 2017 Filed Mar 2, 2017 06:05 UTC	Kite Pharma, Inc. KITE · Entity 172664	Exercise / conversionCommon Stock	31,601	$51.43	$1,625,239.43	Disclosure SEC source: 0000899243-17-005888 · doc4.xml · nonDerivative · entry 1 Kim Helen Susan · CIK 0001422772 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,265 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 22, 2016 Filed Dec 27, 2016 17:29 UTC	Kite Pharma, Inc. KITE · Entity 172664	GrantEmployee Stock Option (Right to Buy) · Derivative	38,500	$0.00 Strike: $46.09	$0.00	Disclosure SEC source: 0001209191-16-156834 · doc4.xml · derivative · entry 2 Kim Helen Susan · CIK 0001422772 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,500 Underlying: Common Stock · 38,500 shares Expires 2026-12-22 F1 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable on the first anniversary of the grant date, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.